Transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare MC4R pathway diseases by rapidly advancing care and precision medicines addressing the root cause Forward Looking Statements ® ✓ Granted EC marketing authorization for IMCIVREE for BBS; received early access authorization in France ✓ Completed enrollment in Phase 3 trial in pediatric patients ✓ Entered non-dilutive RIFA agreement with HealthCare Royalty for up to $100 million Phase 3 weekly formul ...